Apellis enters $300M ATM offering with Cowen; prior Jefferies facility terminated

Apellis Pharmaceuticals, Inc.

Entered Sales Agreement with Cowen to sell up to $300M of common stock via at-the-market offerings.
Prior $300M ATM with Jefferies terminated; no shares had been sold under that agreement.
Cowen will receive up to 3.0% commission on gross proceeds from sales.
ATM offering made under existing shelf registration statement (File No. 333-269899).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Apellis Pharmaceuticals, Inc. terminated Open Market Sale Agreement SM with Jefferies LLC valued at up to $300.0 million (effective 2023-10-31).

Action: termination
Agreement: atm program
Counterparty: Jefferies LLC
Value: up to $300.0 million
Effective: 2023-10-31

Exact text from the filing

In connection with the entry into the Agreement, on October 31, 2023, the Company terminated its prior Open Market Sale Agreement SM , dated as of January 20, 2022 (the “Prior Agreement”), by and between the Company and Jefferies LLC (“Jefferies”), in accordance with its terms.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Apellis Pharmaceuticals, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $300.0 million (effective 2023-11-01).

Action: entry
Agreement: atm program
Counterparty: Cowen and Company, LLC
Value: up to $300.0 million
Effective: 2023-11-01

Exact text from the filing

On November 1, 2023, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Sales Agreement (the “Agreement”) with Cowen and Company, LLC, as agent (“Cowen”), pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share (the “Shares”), from time to time through Cowen (the “Offering”).

View on SEC.gov

Browse all material agreements →

Apellis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-267745

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.